Dabigatran etexilate: A pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

PharmacoEconomics

Volumn 30, Issue 9, 2012, Pages 841-855

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Atrial fibrillation; Cost effectiveness; Cost utility; Dabigatran etexilate; general; Pharmacoeconomics; Thrombin inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; WARFARIN;

COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CREATININE CLEARANCE; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; FOLLOW UP; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; EMBOLISM; HUMANS; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; STROKE; WARFARIN;

EID: 84864968277     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11209130-000000000-00000     Document Type: Review

References (42)

1. Deedwania PC, Huang GW. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with a trial fibrillation. AmJ Cardiovasc Drug 2011 114 265-75
2. Camm AJ, Kirchlof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of CardiologyESC). Eur Heart J 2010 Oct 3119 2369-429
3. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012 1412 e531S-575S
4. Olesen JB, Torp-Pedersen C, Hansen ML. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwiDe cohort study. Thromb Haemost. Epub 2012 Apr 3
5. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ 2011 343: D6333
6. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011 1541 1-11
7. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants. Chest 1998 1145 Suppl. 445S-69S
8. European Medicines Agency. Pradaxa dabigatran etexilate capsules summary of product characteristics [online]. Available from URL: Http://www.ema.europa. eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000829/ WC500041059.pdf [Accessed 2012 Mar 23]
9. Boehringer Ingelheim Pharmaceuticals Inc.. Pradaxa dabigatran etexilate mesylate capsules US prescribing information [online]. Available from URL: Http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser? docBase=renetnt&folderpath=/Prescribing%20Information/ PIs/Pradaxa/Pradaxa. pdf [Accessed 2012 Mar 21]
10. European Medicines Agency. Xarelto-rivaroxaban summary of product characteristics [online]. Available from URL: Http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000944/WC 500057108.pdf [Accessed 2012 Mar 27]
11. Savelieva I, Camm J. Update on atrial fibrillation: Part 1. Clin Cardiol 2008 Feb 312 55-62
12. Heeringa J, Van Der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006 278 949-53
13. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: The Framingham Study. Stroke 1996 2710 1760-4 (Pubitemid 26332500)
14. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics, 2012 update: A report from the American Heart Association. Circulation 2012 Jan 1251 e2-220
15. Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: A systematic review of the recent literature. Europace 2011 Oct 1310 1375-85
16. Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health 2012 Mar 152 240-8
17. Garnock-Jones KP. Dabigatran etexilate: A review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011 111 57-72
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17 36112 1139-51
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial [letter]. N Engl J Med 2010 36319 1875-6
20. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012 Mar 1725 397-402
21. Hart RG, Diener H-C, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke. Epub 2012 Apr 5
22. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapyRE-LY) trial. Circulation 2011 May 12321 2363-72
23. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011 12322 2562-70
24. Kamel H, Johnston SC, Easton JD, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012 Mar 433 881-3
25. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012 987 573-8
26. National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation [NICE technology appraisal guidance no. 249 online]. Available from URL: Http:// www.nice.org.uk/ta249 [Accessed 2012 Mar 19]
27. Sorensen SV, Kansal AR, Connolly S, et al. Costeffectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost 2011 May 1055 908-19
28. LangkilDe L, Asmussen M, Overgaard M, et al. Costeffectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation: ApplyingRE-LYto clinical practice in Denmark. J Med Econ. Epub 2012Mar 22
29. National Institute for Health and Clinical Excellence. GuiDe to the methods of technology appraisal. London: NICE, 2008 Jun [online]. Available from URL: Http://www. nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune 2008.pdf [Accessed 2012 Feb 7]
30. Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health 2010 136 853-6
31. Jönsson B. Changing health environment: The challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004 22 Suppl. 4: 5-10 (Pubitemid 40066088)
32. Eichler H-G, Kong SX, Gerth WC, et al. Use of costeffectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004 75 518-28 (Pubitemid 39390832)
33. Freeman JV, Turakhia MP. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation [letter]. Ann Intern Med 2011 1548 570-1
34. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 2008 Oct 510 1365-72
35. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/ AHA/HRS focused updates incorporated into the ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011 Mar 12310 e269-367
36. Stangier J, Rathgen K, Stahle H. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010 494 259-68
37. Beasley BN, Unger EF, Temple R. Anticoagulant options: Why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011 36419 1788-90
38. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practicethe real world) perspective. Thromb J 2011 Jul 9: 12
39. Platt AB, Localio AR, Bresinger CM, et al. Can we predict daily adherence to warfarin? Results from the international normalized ratio adherence and geneticsIN-RANGE) study. Chest 2010 1374 883-9
40. Adcock AK, Lee-Iannotti JK, Aquilar MI, et al. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist 2012 Mar 182 102-7
41. Reddy P, Atay JK, Selbovitz LG, et al. Dabigatran: A review of clinical and pharmacoeconomic evidence. Crit Pathways Cardiol 2011 103 117-27
42. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. New Engl J Med 2011 Sep 36510 883-91